We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+10.64%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$630M
AUM Growth
+$112M
Cap. Flow
+$86.5M
Cap. Flow %
13.74%
Top 10 Hldgs %
36.68%
Holding
120
New
21
Increased
31
Reduced
30
Closed
24

Top Buys

1
MLYS icon
Mineralys Therapeutics
MLYS
+$26.1M
2
RARE icon
Ultragenyx Pharmaceutical
RARE
+$11.5M
3
BBIO icon
BridgeBio Pharma
BBIO
+$9.97M
4
CLBT icon
Cellebrite
CLBT
+$9.52M
5
PANW icon
Palo Alto Networks
PANW
+$8.87M

Top Sells

1
ANNX icon
Annexon
ANNX
+$6.61M
2
SEDG icon
SolarEdge
SEDG
+$5.4M
3
ORIC icon
Oric Pharmaceuticals
ORIC
+$5.3M
4
ATXS
Astria Therapeutics
ATXS
+$4.66M
5
DYN icon
Dyne Therapeutics
DYN
+$4.01M

Sector Composition

1 Healthcare 74.06%
2 Technology 14.11%
3 Utilities 1.21%
4 Consumer Discretionary 1.06%
5 Industrials 0.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CTNM
76
Contineum Therapeutics
CTNM
$532M
$2.27M 0.36%
173,475
– –
TENX icon
77
Tenax Therapeutics
TENX
$420M
$2.17M 0.35%
136,015
-54,096
-28% -$732K
PRLD icon
78
Prelude Therapeutics
PRLD
$335M
$1.91M 0.3%
558,339
+435,587
+355% +$1.14M
ASND icon
79
Ascendis Pharma A/S
ASND
$17.1B
$1.83M 0.29%
8,000
-3,000
-27% -$673K
VSTM icon
80
Verastem
VSTM
$530M
$1.82M 0.29%
343,678
– –
VYGR icon
81
Voyager Therapeutics
VYGR
$192M
$1.81M 0.29%
469,761
+130,000
+38% +$512K
STTK icon
82
Shattuck Labs
STTK
$719M
$1.81M 0.29%
280,786
+85,574
+44% +$406K
EVMN
83
Evommune Inc
EVMN
$437M
$1.8M 0.29%
78,234
-87,913
-53% -$1.99M
BIOA
84
BioAge Labs
BIOA
$1.01B
$1.51M 0.24%
86,518
-156,517
-64% -$3.01M
OLMA icon
85
CALL
Olema Pharmaceuticals
OLMA
$1B
$1.49M 0.24%
+100,000
New +$2.23M
ORGO icon
86
Organogenesis Holdings
ORGO
$337M
$1.3M 0.21%
+550,000
New +$1.91M
CRIS icon
87
Curis
CRIS
$9.02M
$1.09M 0.17%
+99,747
New +$1.86M
BMY icon
88
Bristol-Myers Squibb
BMY
$124B
$1.06M 0.17%
17,500
– –
CTMX icon
89
CytomX Therapeutics
CTMX
$788M
$1.03M 0.16%
+220,000
New +$1.12M
NICE icon
90
Nice
NICE
$5.87B
$619K 0.1%
+5,611
New +$641K
HOWL icon
91
Werewolf Therapeutics
HOWL
$17.9M
$522K 0.08%
626,810
– –
SKYE icon
92
Skye Bioscience
SKYE
$22.8M
$417K 0.07%
678,928
+200,000
+42% +$163K
DTIL icon
93
Precision BioSciences
DTIL
$203M
$220K 0.03%
40,000
-356,116
-90% -$1.64M
APRE icon
94
Aprea Therapeutics
APRE
$8.79M
$206K 0.03%
270,000
– –
FHTX icon
95
Foghorn Therapeutics
FHTX
$305M
$58.4K 0.01%
+12,224
New +$67.1K
AMD icon
96
Advanced Micro Devices
AMD
$808B
– –
-18,040
Closed -$3.86M
ANNX icon
97
Annexon
ANNX
$950M
– –
-1,316,212
Closed -$6.61M
APLT
98
DELISTED
Applied Therapeutics
APLT
– –
-50,000
Closed -$5K
ATXS
99
DELISTED
Astria Therapeutics
ATXS
– –
-355,725
Closed -$4.66M
AVGO icon
100
Broadcom
AVGO
$1.76T
– –
-9,755
Closed -$3.38M
1 2 3
4
5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
SCM
Schnieders Capital Management Pasadena, California $629M AUM 28.1% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
PA
Probity Advisors Dallas, Texas $631M AUM 17.4% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
WAAG
Wealth Alliance Advisory Group Wichita, Kansas $632M AUM 18.54% 1-Year Est. Return

Sphera Funds Management's Q1 2026 Portfolio in Review

As of Q1 2026, Sphera Funds Management held 120 positions worth $630M, up 22% from $517M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Sphera Funds Management deployed $86.5M of net new capital in Q1 2026, opening 21 new positions and adding to 31 existing holdings. Its largest new stake was Cellebrite: 631,521 shares worth $8.7M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 80% a quarter earlier, followed by Technology and Utilities.

On the sell side, the largest reduction was SolarEdge, an estimated $5.4M trimmed.

  • Sphera Funds Management's largest Q1 2026 buy was Cellebrite: 631,521 shares worth $8.7M.
  • Sphera Funds Management added most to Mineralys Therapeutics in Q1 2026, an estimated $26.1M increase.
  • Sphera Funds Management's biggest Q1 2026 reduction was SolarEdge, cutting an estimated $5.4M.
  • Sphera Funds Management fully exited Annexon in Q1 2026, selling an estimated $6.61M.
  • Sphera Funds Management's ten largest holdings make up 37% of its $630M portfolio in Q1 2026.
  • Sphera Funds Management opened 21 new positions and closed 24 in Q1 2026.
  • Sphera Funds Management's portfolio value rose 22% quarter-over-quarter to $630M.

Based on Sphera Funds Management's 13F filing for Q1 2026, filed 15 May 2026.